ISV-305
Phase 3Small molecule
Sun Pharmaceutical Industries LimitedISV-305 is one of 54 small molecule programs targeting Blepharitis. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
219 competitors in Cataract
#DrugCompanyPhaseTrials
1Pred Forte
NovartisPhase 3
Bayer Aspirin
BayerPhase 3
Lotemax
BBausch & Lomb Incorporated
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Isopto Carpine
AAdvanz Pharma
Phase 3
Avastin
BBio-Thera Solutions
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Intranasal Dexmedetomidine
BBaudax Bio
Phase 3
Mapracorat
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cataract2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ISV-305. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details